Clinuvel Pharmaceuticals Limited Stock Xetra
Stocks
UR9
AU000000CUV3
Pharmaceuticals
OTC Markets Traded| Market Cap | 504M 348M 305M 281M 263M 494M 32.81B 3.38B 1.31B 16.22B 1.31B 1.28B 56.23B | P/E 2026 * |
14x | P/E 2027 * | 13.2x |
|---|---|---|---|---|---|
| Enterprise Value | 250M 173M 151M 140M 131M 245M 16.29B 1.68B 649M 8.05B 648M 634M 27.91B | EV / Sales 2026 * |
2.51x | EV / Sales 2027 * | 2.07x |
| Free-Float |
83.79% | Yield 2026 * |
0.61% | Yield 2027 * | 0.8% |
Last Transcript: Clinuvel Pharmaceuticals Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 63 | 2005-10-31 |
Peter Vaughan
DFI | Director of Finance/CFO | 42 | 2024-06-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Karen Agersborg
BRD | Director/Board Member | - | 2018-01-28 |
Susan Smith
BRD | Director/Board Member | - | 2019-09-22 |
| Chairman | - | 2023-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 348M | |
| +2.06% | +3.76% | +21.48% | -11.62% | 64.39B | |
| +0.74% | +3.52% | +51.88% | +225.16% | 56.12B | |
| -3.10% | +34.30% | +34.30% | +34.30% | 40.54B | |
| -2.36% | -1.25% | -50.98% | -58.84% | 37.98B | |
| +6.97% | +9.89% | +71.34% | -23.65% | 31.89B | |
| +12.59% | +5.18% | +147.68% | -44.25% | 26.69B | |
| +5.78% | +15.81% | +66.37% | +84.42% | 22.73B | |
| -1.25% | -1.31% | -2.84% | +151.34% | 16.66B | |
| -0.81% | +5.91% | +63.81% | +125.65% | 16.6B | |
| Average | +2.06% | +4.32% | +44.78% | +53.61% | 34.84B | |
| Weighted average by Cap. | +1.96% | +4.11% | +39.81% | +49.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 99.46M 68.67M 60.21M 55.5M 51.96M 97.44M 6.48B 667M 258M 3.2B 258M 252M 11.1B | 105M 72.74M 63.78M 58.79M 55.04M 103M 6.86B 707M 273M 3.39B 273M 267M 11.76B |
| Net income | 35.97M 24.83M 21.77M 20.07M 18.79M 35.24M 2.34B 241M 93.34M 1.16B 93.25M 91.21M 4.01B | 38.2M 26.38M 23.13M 21.32M 19.96M 37.42M 2.49B 256M 99.14M 1.23B 99.04M 96.88M 4.26B |
| Net Debt | -254M -175M -154M -142M -133M -249M -16.52B -1.7B -658M -8.17B -658M -643M -28.32B | -286M -197M -173M -160M -149M -280M -18.63B -1.92B -742M -9.21B -742M -725M -31.93B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
